Cas:196877-76-6 5-(bromomethyl)-3-(4-methoxyphenyl)-1,2-oxazole manufacturer & supplier

Chemical Name:5-(bromomethyl)-3-(4-methoxyphenyl)-1,2-oxazole

CAS.NO:196877-76-6

Synonyms:5-(bromomethyl)-3-(4-methoxyphenyl)-1,2-oxazole

Molecular Formula:C₁₁H₁₀BrNO₂

Molecular Weight:268.10700

HS Code:2934999090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:35.26000

Exact Mass:266.98900

LogP:3.24510

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 5-(bromomethyl)-3-(4-methoxyphenyl)-1,2-oxazole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-(bromomethyl)-3-(4-methoxyphenyl)-1,2-oxazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-(bromomethyl)-3-(4-methoxyphenyl)-1,2-oxazole Use and application,5-(bromomethyl)-3-(4-methoxyphenyl)-1,2-oxazole technical grade,usp/ep/jp grade.

Related News: With the continuous advancement of economic globalization, the division of labor and cooperation around the world has become increasingly apparent. The fine chemical industry has the foundation of global division of labor and cooperation due to its long and complex industrial chain. 5-(bromomethyl)-3-(4-methoxyphenyl)-1,2-oxazole manufacturer The insulin-only and bihormonal configurations may be helpful in diabetes. 5-(bromomethyl)-3-(4-methoxyphenyl)-1,2-oxazole supplier Physiologically relevant interactions with test molecules or protein ligands can be identified with high sensitivity and specificity. 5-(bromomethyl)-3-(4-methoxyphenyl)-1,2-oxazole vendor Retrogenix��s extensive library of human proteins make it uniquely placed for assessing candidate antibodies for target binding. 5-(bromomethyl)-3-(4-methoxyphenyl)-1,2-oxazole factory In approving the first new Alzheimer’s drug in nearly 20 years, the U.S. Food and Drug Administration is taking its biggest risk yet with a strategy that allows new therapies onto the market without strong evidence that they work, regulatory and scientific experts say.